Skip to main content

Table 3 Clinical characteristics of the 8 cases of NVP-induced liver injury. *HLAB5701 tested absent

From: Clinical and genetic factors associated with increased risk of severe liver toxicity in a monocentric cohort of HIV positive patients receiving nevirapine-based antiretroviral therapy

  Pt 1 Pt 2 Pt 3 Pt 4 Pt 5 Pt 6 Pt 7 Pt 8
HCV coinfection no yes yes yes yes no yes yes
ARV status Experienced Experienced Experienced Experienced Naive Experienced Experienced Experienced
Concomitant ARV d4T + 3TC d4T + 3TC ABC* + 3TC AZT + 3TC AZT + 3TC d4T + ddi AZT + 3TC d4T + ddi
NVP exposure before treatment interruption (days) 28 61 29 28 58 28 50 38
Concomitant medication none none Vitamin D and folinic acid none Phenobarbital and alprazolam none None Folinic acid
Symptoms Nausea and severe weakness none Nausea none Weakness none Nausea None
Required hospitalization yes no yes no no no no no
Outcome Recovered without sequelae Recovered without sequelae Recovered without sequelae Recovered without sequelae Recovered without sequelae Recovered without sequelae Recovered without sequelae Recovered without sequelae
RUCAM Probable Probable Possible Probable Possible Probable Probable Possible
  1. Abbreviations: Pt Patient, HCV Hepatitis C virus, ARV Antiretroviral, d4T Stavudine, 3TC Lamivudine, ABC Abacavir, AZT Zidovudine, ddi Didanosine, RUCAM Roussel Uclaf Causality Assessment Method